Skip to content
Menu
About Us
Company Overview
Management
Board of Directors
Our Science
Overview of Assets
Science
Pipeline
Clinical Trials
Expanded Access Policy
Newsroom
Press Releases
Events & Presentations
Investor Relations
Corporate Governance
Financial Information
Annual Reports & Proxy Statements
Investor Contact Info
Contact
Close Menu
Press Releases
July 19, 2023
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
View/download press release »
Sign up to receive press releases via email
Leave this field empty if you're human:
